ArtVentive Medical Group, Inc.: 10-Q filed 2013-05-20

Name: ArtVentive Medical Group, Inc.: 10-Q filed 2013-05-20
Creator: ArtVentive Medical Group, Inc.
License: https://creativecommons.org/licenses/by/4.0/

What ArtVentive Medical Group, Inc. reported in its quarterly report filed 2013-05-20 (fiscal Q1 2013): 18 published measures, 43 facts as tagged in accession 0001056520-13-000123.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-05-20
Fiscal period: fiscal Q1 2013
Accession: 0001056520-13-000123 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ArtVentive Medical Group, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-03-31	833,718	USD
At 2012-12-31	578,830	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2013-03-31	469,896	USD
At 2012-12-31	418,696	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-553,969	USD	90
2007-01-23 to 2013-03-31	-5,299,925	USD	2260
2012-01-01 to 2012-03-31	-166,446	USD	91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-389,529	USD	90
2007-01-23 to 2013-03-31	-5,002,534	USD	2260
2012-01-01 to 2012-03-31	-56,635	USD	91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	650,000	USD	90
2007-01-23 to 2013-03-31	5,786,080	USD	2260

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-3,551	USD	90
2007-01-23 to 2013-03-31	-8,795	USD	2260

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	51,222,598	shares	90
2012-01-01 to 2012-03-31	49,156,941	shares	91

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2013-03-31	6,871	USD
At 2012-12-31	3,903	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-554,204	USD	90
2007-01-23 to 2013-03-31	-5,304,377	USD	2260
2012-01-01 to 2012-03-31	-166,453	USD	91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-03-31	775,799	USD
At 2012-12-31	523,879	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-03-31	363,822	USD
At 2012-12-31	160,134	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-03-31	363,346	USD
At 2012-12-31	160,050	USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	225,247	USD	90
2007-01-23 to 2013-03-31	1,790,935	USD	2260
2012-01-01 to 2012-03-31	73,714	USD	91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	328,374	USD	90
2007-01-23 to 2013-03-31	3,465,967	USD	2260
2012-01-01 to 2012-03-31	92,670	USD	91

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-03-31	5,718,223	USD
At 2012-12-31	5,113,703	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2013-03-31	-1,426	USD
At 2012-12-31	-843	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	-553,969	USD	90
2007-01-23 to 2013-03-31	-5,299,925	USD	2260
2012-01-01 to 2012-03-31	-166,446	USD	91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-03-31	138,296	USD	90
2007-01-23 to 2013-03-31	148,346	USD	2260
2012-01-01 to 2012-03-31	79,199	USD	91

Inspect the source

Entity: ArtVentive Medical Group, Inc. / CIK 0001405249
Captured: 2026-09-23 02:53 UTC
SEC response SHA-256: 01b8937f2876d513617b1d921d4a98ec6f536680d197470785bad286f4947f07

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001405249.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))